ciprofloxacin has been researched along with Kahler Disease in 12 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a single-center open-label prospective study, a total of 134 marrow transplant recipients with hematologic malignancies were randomly assigned to a bacterial decontamination medication using metronidazole and ciprofloxacin (n = 68) or ciprofloxacin alone (n = 66) during 5 weeks posttransplant." | 9.09 | Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and ( Beelen, DW; Elmaagacli, A; Hirche, H; Müller, KD; Schaefer, UW, 1999) |
| "To evaluate the impact of cessation of ciprofloxacin prophylaxis during stem cell transplantation for multiple myeloma." | 7.91 | Ciprofloxacin prophylaxis during autologous stem cell transplantation for multiple myeloma in patients with a high rate of fluoroquinolone-resistant gram-negative bacteria colonization. ( Gabalec, F; Paterova, P; Radocha, J; Zak, P; Zavrelova, A, 2019) |
| " We compared the incidence of bacterial-related complications among 356 patients with multiple myeloma (MM) (n = 202) and lymphoma (n = 154) who underwent AHCT with (n = 177) or without (n = 179) ciprofloxacin prophylaxis between 03/2007 and 10/2012 and between 10/2012 and 07/2016, respectively, at a single centre." | 7.88 | Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. ( Bishara, J; Gurion, R; Herscovici, C; Lahav, M; Magen, H; Moshe, M; Naparstek, E; Pasvolsky, O; Peck, A; Raanani, P; Rozovski, U; Sela-Navon, M; Shargian, L; Vaxman, I; Vidal, L; Wolach, O; Yahav, D; Yeshurun, M, 2018) |
| "The addition of doxycycline to standard prophylaxis with ciprofloxacin seems to reduce the number of NF episodes and documented bacterial infections in patients with MM undergoing ASCT, without increasing rate of serious complications." | 7.88 | Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma. ( Davidson, J; Drabick, JJ; Hale, CM; Sivik, JM; Talamo, G, 2018) |
| "In a single-center open-label prospective study, a total of 134 marrow transplant recipients with hematologic malignancies were randomly assigned to a bacterial decontamination medication using metronidazole and ciprofloxacin (n = 68) or ciprofloxacin alone (n = 66) during 5 weeks posttransplant." | 5.09 | Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and ( Beelen, DW; Elmaagacli, A; Hirche, H; Müller, KD; Schaefer, UW, 1999) |
| "To evaluate the impact of cessation of ciprofloxacin prophylaxis during stem cell transplantation for multiple myeloma." | 3.91 | Ciprofloxacin prophylaxis during autologous stem cell transplantation for multiple myeloma in patients with a high rate of fluoroquinolone-resistant gram-negative bacteria colonization. ( Gabalec, F; Paterova, P; Radocha, J; Zak, P; Zavrelova, A, 2019) |
| "The objective of the current retrospective study was to compare differences in rate of breakthrough infections for ciprofloxacin vs levofloxacin prophylaxis in autologous hematopoietic stem-cell transplant (HSCT) patients treated for multiple myeloma." | 3.88 | Ciprofloxacin vs levofloxacin for prophylaxis during hematopoietic stem-cell transplantation. ( Copeland, V; McLaughlin, M; Trifilio, S, 2018) |
| " We compared the incidence of bacterial-related complications among 356 patients with multiple myeloma (MM) (n = 202) and lymphoma (n = 154) who underwent AHCT with (n = 177) or without (n = 179) ciprofloxacin prophylaxis between 03/2007 and 10/2012 and between 10/2012 and 07/2016, respectively, at a single centre." | 3.88 | Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. ( Bishara, J; Gurion, R; Herscovici, C; Lahav, M; Magen, H; Moshe, M; Naparstek, E; Pasvolsky, O; Peck, A; Raanani, P; Rozovski, U; Sela-Navon, M; Shargian, L; Vaxman, I; Vidal, L; Wolach, O; Yahav, D; Yeshurun, M, 2018) |
| "The addition of doxycycline to standard prophylaxis with ciprofloxacin seems to reduce the number of NF episodes and documented bacterial infections in patients with MM undergoing ASCT, without increasing rate of serious complications." | 3.88 | Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma. ( Davidson, J; Drabick, JJ; Hale, CM; Sivik, JM; Talamo, G, 2018) |
| "Multiple myeloma was the main indication for ASCT in both groups." | 1.38 | Ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy and autologous stem cell transplantation (ASCT) - a single-center experience. ( Kopka, P; Pluta, A; Robak, T; Szmigielska-Kaplon, A; Wierzbowska, A; Wolska, A, 2012) |
| "In ciprofloxacin-treated patients the flora were almost completely ciprofloxacin-resistant, whereas in the control groups resistant flora were detected only occasionally." | 1.28 | Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. ( Huovinen, P; Kotilainen, P; Nikoskelainen, J, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miyamoto, Y | 1 |
| Udaka, K | 1 |
| Sekimoto, E | 1 |
| Shibata, H | 1 |
| Otsuka, K | 1 |
| Mori, K | 1 |
| Shigekiyo, T | 1 |
| Ozaki, S | 1 |
| Copeland, V | 1 |
| McLaughlin, M | 1 |
| Trifilio, S | 1 |
| Yeshurun, M | 1 |
| Vaxman, I | 1 |
| Shargian, L | 1 |
| Yahav, D | 1 |
| Bishara, J | 2 |
| Pasvolsky, O | 1 |
| Wolach, O | 1 |
| Lahav, M | 1 |
| Gurion, R | 1 |
| Magen, H | 1 |
| Vidal, L | 1 |
| Herscovici, C | 1 |
| Peck, A | 1 |
| Moshe, M | 1 |
| Sela-Navon, M | 1 |
| Naparstek, E | 1 |
| Raanani, P | 1 |
| Rozovski, U | 1 |
| Sivik, JM | 1 |
| Davidson, J | 1 |
| Hale, CM | 1 |
| Drabick, JJ | 1 |
| Talamo, G | 1 |
| Zavrelova, A | 1 |
| Paterova, P | 1 |
| Gabalec, F | 1 |
| Zak, P | 1 |
| Radocha, J | 1 |
| Arakawa, R | 1 |
| Mori, N | 1 |
| Kagawa, N | 1 |
| Higuchi, A | 1 |
| Tanaka, M | 1 |
| Aoki, Y | 1 |
| Seki, S | 1 |
| Suzuki, R | 1 |
| Wolska, A | 1 |
| Robak, T | 1 |
| Szmigielska-Kaplon, A | 1 |
| Pluta, A | 1 |
| Kopka, P | 1 |
| Wierzbowska, A | 1 |
| Vesole, DH | 1 |
| Oken, MM | 1 |
| Heckler, C | 1 |
| Greipp, PR | 1 |
| Katz, MS | 1 |
| Jacobus, S | 1 |
| Morrow, GR | 1 |
| Gabay, B | 1 |
| Samra, Z | 1 |
| Hodak, E | 1 |
| Pitlik, S | 1 |
| Beelen, DW | 1 |
| Elmaagacli, A | 1 |
| Müller, KD | 1 |
| Hirche, H | 1 |
| Schaefer, UW | 1 |
| Tejan-Sie, SA | 1 |
| Avery, RK | 1 |
| Mossad, SB | 1 |
| Kotilainen, P | 1 |
| Nikoskelainen, J | 1 |
| Huovinen, P | 1 |
1 review available for ciprofloxacin and Kahler Disease
| Article | Year |
|---|---|
Hematopoietic neoplasms accompanied by severe enterocolitis due to Aeromonas species.
Topics: Aeromonas; Aged; Anti-Bacterial Agents; Antineoplastic Agents; Ciprofloxacin; Diarrhea; Enterocoliti | 2017 |
2 trials available for ciprofloxacin and Kahler Disease
| Article | Year |
|---|---|
Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; | 2012 |
Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bone Marrow Transplantation; Ciprofloxacin; Drug Therapy, | 1999 |
9 other studies available for ciprofloxacin and Kahler Disease
| Article | Year |
|---|---|
Ciprofloxacin vs levofloxacin for prophylaxis during hematopoietic stem-cell transplantation.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Female; Follow-U | 2018 |
Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Ciprofloxacin; Controlled Be | 2018 |
Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Doxycycline; Female; Hemato | 2018 |
Ciprofloxacin prophylaxis during autologous stem cell transplantation for multiple myeloma in patients with a high rate of fluoroquinolone-resistant gram-negative bacteria colonization.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Carrier State; Cip | 2019 |
[Meningococcal Septicemia Revealing Multiple Myeloma: A Case Report].
Topics: Ciprofloxacin; Disseminated Intravascular Coagulation; Humans; Male; Meningococcal Infections; Middl | 2016 |
Ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy and autologous stem cell transplantation (ASCT) - a single-center experience.
Topics: Adult; Aged; Ciprofloxacin; Female; Fluoroquinolones; Humans; Male; Melphalan; Middle Aged; Multiple | 2012 |
Cellulitis caused by Citrobacter diversus in a patient with multiple myeloma.
Topics: Anti-Infective Agents; Bacteremia; Cellulitis; Ciprofloxacin; Citrobacter; Diagnosis, Differential; | 1998 |
Mycobacterium fortuitum osteomyelitis in a peripheral blood stem cell transplant recipient.
Topics: Administration, Oral; Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Biopsy; Cefoxit | 2000 |
Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin.
Topics: Aged; Ciprofloxacin; Coagulase; Drug Resistance, Microbial; Female; Humans; Immune Tolerance; Leukem | 1990 |